Shoulder Innovations (SI) Canaccord Genuity's 46th Annual Growth Conference summary
Event summary combining transcript, slides, and related documents.
Canaccord Genuity's 46th Annual Growth Conference summary
12 Aug, 2026Market overview and growth drivers
Shoulder arthroplasty is a $2.8 billion global market, growing at over 10% annually, with a significant shift from inpatient to outpatient care, especially in ambulatory surgery centers following CMS reimbursement approval in January 2024.
The company targets 1,800 high-volume surgeons, representing 80% of procedures, enabling a focused and efficient commercial model.
Reverse shoulder replacements now account for 70% of procedures, reflecting evolving clinical practice and biomechanics.
The transition to ambulatory surgery centers is expected to drive substantial growth, with outpatient procedures rising from 10% to 30% by the end of 2025.
The company has achieved 60% revenue growth year-to-date, with gross margins in the upper 70% range and a strong cash position.
Product innovation and differentiation
The InSet Glenoid technology addresses glenoid component loosening, achieving 100% survivorship at 8.7 years and an 87% reduction in rocking horse motion.
Modular implant design allows intraoperative transition between anatomic and reverse procedures, enhancing surgical flexibility.
Instrument footprint is reduced to two trays, lowering costs and simplifying workflow in ambulatory settings.
Automated, AI-enabled, CT-based preoperative planning improves surgical accuracy and is being integrated with a portable robotic solution, with 510(k) filing planned for the first half of 2027.
New product launches include InSet 135 for fractures, N22 Glenosphere for metal sensitivity, TPS reverse baseplate, and a reusable guide system.
Commercial strategy and operational efficiency
The commercial model combines a 1099 independent sales force with over 40 W2 leaders and a Customer Experience in Medical Education (CEME) team, enabling targeted surgeon engagement and rapid growth.
Over 90 CEME events in the first half of the year engaged 160 practitioners, driving first-use adoption.
Cost-down initiatives and a low-inventory model support improved free cash flow and working capital efficiency, with cash burn reduced from $15M to $9M quarter-over-quarter.
The company is focused on expanding its core customer base, increasing average selling prices, and exploring adjacent markets and international expansion.
Latest events from Shoulder Innovations
- Registering $300M in securities and 8.1M shares for resale, targeting ASC-driven growth.SI
Registration filing - Q2 revenue up 56% YoY, guidance raised, and implant sales and innovation drive growth.SI
Q2 2026 - Director elections and auditor ratification approved; no stockholder questions submitted.SI
AGM 2026 - Innovative implants and AI-driven planning fuel rapid growth in the $2.8B shoulder arthroplasty market.SI
Investor presentation - Q1 2026 revenue surged 65% to $16.7M, with margin gains and a raised full-year outlook.SI
Q1 2026 - Annual meeting to elect directors and ratify auditor, with strong governance and risk oversight.SI
Proxy filing - Vote on director elections and auditor ratification at the June 26, 2026 annual meeting.SI
Proxy filing - Q4 revenue up 65% year-over-year; 2026 guidance targets 31–37% growth with strong margins.SI
Q4 2025 - Strong Q2 growth and innovative, efficient solutions drive momentum in the shoulder arthroplasty market.SI
Morgan Stanley 23rd Annual Global Healthcare Conference